{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T22:51:22Z","timestamp":1785711082765,"version":"3.56.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,2]]},"DOI":"10.7759\/cureus.113821","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T22:21:02Z","timestamp":1785709262000},"source":"Crossref","is-referenced-by-count":0,"title":["A Review of the Current Literature Regarding Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure With Preserved Ejection Fraction and Timing of Initiating Therapy"],"prefix":"10.7759","author":[{"given":"Mark","family":"Sahyouni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag","family":"Lodha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Joseph Varughese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197112232852601","article-title":"The natural history of congestive heart failure: the Framingham study","volume":"285","author":"McKee PA","year":"1971","unstructured":"McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971, 285:1441-6. 10.1056\/NEJM197112232852601","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.2020","article-title":"Heart failure with preserved ejection fraction: a review","volume":"329","author":"Redfield MM","year":"2023","unstructured":"Redfield MM, Borlaug BA. Heart failure with preserved ejection fraction: a review. JAMA. 2023, 329:827-38. 10.1001\/jama.2023.2020","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp2305181","article-title":"Heart failure with preserved ejection fraction","volume":"392","author":"Cannata A","year":"2025","unstructured":"Cannata A, McDonagh TA. Heart failure with preserved ejection fraction. N Engl J Med. 2025, 392:173-84. 10.1056\/NEJMcp2305181","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction: JACC scientific statement","volume":"81","author":"Borlaug BA","year":"2023","unstructured":"Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart failure with preserved ejection fraction: JACC scientific statement. J Am Coll Cardiol. 2023, 81:1810-34. 10.1016\/j.jacc.2023.01.049","journal-title":"J Am Coll Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson MM","year":"2023","unstructured":"Kittleson MM, Panjrath GS, Amancherla K, et al.. 2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023, 81:1835-78. 10.1016\/j.jacc.2023.03.393","journal-title":"J Am Coll Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02756-3","article-title":"Heart failure with preserved ejection fraction: everything the clinician needs to know","volume":"403","author":"Campbell P","year":"2024","unstructured":"Campbell P, Rutten FH, Lee MM, Hawkins NM, Petrie MC. Heart failure with preserved ejection fraction: everything the clinician needs to know. Lancet. 2024, 403:1083-92. 10.1016\/S0140-6736(23)02756-3","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2025.11.004","article-title":"Mechanistic insights and clinical horizons of SGLT2 inhibitors in heart failure management","volume":"36","author":"Vahid SS","year":"2026","unstructured":"Vahid SS, Jahromi MS, Moukarbel GV, Hill JW. Mechanistic insights and clinical horizons of SGLT2 inhibitors in heart failure management. Trends Cardiovasc Med. 2026, 36:193-201. 10.1016\/j.tcm.2025.11.004","journal-title":"Trends Cardiovasc Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.030012","article-title":"Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials","volume":"136","author":"Lytvyn Y","year":"2017","unstructured":"Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZ. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation. 2017, 136:1643-58. 10.1161\/CIRCULATIONAHA.117.030012","journal-title":"Circulation"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter\u00a02\u00a0inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker TA","year":"2020","unstructured":"Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter\u00a02\u00a0inhibitors: JACC state-of-the-art review. J Am Coll Cardiol. 2020, 75:422-34. 10.1016\/j.jacc.2019.11.031","journal-title":"J Am Coll Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-025-02516-1","article-title":"Why are SGLT2 inhibitors effective in HFpEF? Implications for interstitial fluid retention and cardio-renal interaction","volume":"49","author":"Masuda T","year":"2026","unstructured":"Masuda T, Kariro K, Morishita Y. Why are SGLT2 inhibitors effective in HFpEF? Implications for interstitial fluid retention and cardio-renal interaction. Hypertens Res. 2026, 49:724-33. 10.1038\/s41440-025-02516-1","journal-title":"Hypertens Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15850","article-title":"Amelioration of endothelial dysfunction by sodium glucose co-transporter 2 inhibitors: pieces of the puzzle explaining their cardiovascular protection","volume":"179","author":"Li X","year":"2022","unstructured":"Li X, Preckel B, Hermanides J, Hollmann MW, Zuurbier CJ, Weber NC. Amelioration of endothelial dysfunction by sodium glucose co-transporter 2 inhibitors: pieces of the puzzle explaining their cardiovascular protection. Br J Pharmacol. 2022, 179:4047-62. 10.1111\/bph.15850","journal-title":"Br J Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack FP","year":"2021","unstructured":"Polack FP, Thomas SJ, Kitchin N, et al.. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2021, 383:2603-15. 10.1056\/NEJMoa2034577","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.09.542","article-title":"Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review","volume":"76","author":"Spertus JA","year":"2020","unstructured":"Spertus JA, Jones PG, Sandhu AT, Arnold SV. Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review. J Am Coll Cardiol. 2020, 76:2379-90. 10.1016\/j.jacc.2020.09.542","journal-title":"J Am Coll Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon SD","year":"2022","unstructured":"Solomon SD, McMurray JJ, Claggett B, et al.. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022, 387:1089-98. 10.1056\/NEJMoa2206286","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt DL","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, et al.. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021, 384:117-28. 10.1056\/NEJMoa2030183","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors AA","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, et al.. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022, 28:568-74. 10.1038\/s41591-021-01659-1","journal-title":"Nat Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3218","article-title":"Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction-results from the EMPULSE trial","volume":"26","author":"Tromp J","year":"2024","unstructured":"Tromp J, Kosiborod MN, Angermann CE, et al.. Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction-results from the EMPULSE trial. Eur J Heart Fail. 2024, 26:963-70. 10.1002\/ejhf.3218","journal-title":"Eur J Heart Fail"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.125.076575","article-title":"Dapagliflozin in patients hospitalized for heart failure: primary results of the DAPA ACT HF-TIMI 68 randomized clinical trial and meta-analysis of sodium-glucose cotransporter-2 inhibitors in patients hospitalized for heart failure","volume":"152","author":"Berg DD","year":"2025","unstructured":"Berg DD, Patel SM, Haller PM, et al.. Dapagliflozin in patients hospitalized for heart failure: primary results of the DAPA ACT HF-TIMI 68 randomized clinical trial and meta-analysis of sodium-glucose cotransporter-2 inhibitors in patients hospitalized for heart failure. Circulation. 2025, 152:1411-22. 10.1161\/CIRCULATIONAHA.125.076575","journal-title":"Circulation"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/01.ccm.0001182532.42330.bc","article-title":"Inpatient SGLT2I initiation and its impact on HFpEF prescription rates and clinical outcomes","volume":"54","author":"Lim L","year":"2026","unstructured":"Lim L, Fattal J, Szwak JA, Brown D, Hiruy A. Inpatient SGLT2I initiation and its impact on HFpEF prescription rates and clinical outcomes. Crit Care Med. 2026, 54:10.1097\/01.ccm.0001182532.42330.bc","journal-title":"Crit Care Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.02.009","article-title":"Efficacy and safety of dapagliflozin in patients with acute heart failure","volume":"83","author":"Cox ZL","year":"2024","unstructured":"Cox ZL, Collins SP, Hernandez GA, et al.. Efficacy and safety of dapagliflozin in patients with acute heart failure. J Am Coll Cardiol. 2024, 83:1295-306. 10.1016\/j.jacc.2024.02.009","journal-title":"J Am Coll Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2022.03.003","article-title":"Minimally clinically important difference in health status scores in patients with HFrEF vs HFpEF","volume":"10","author":"Butler J","year":"2022","unstructured":"Butler J, Shahzeb Khan M, Lindenfeld J, et al.. Minimally clinically important difference in health status scores in patients with HFrEF vs HFpEF. JACC Heart Fail. 2022, 10:651-61. 10.1016\/j.jchf.2022.03.003","journal-title":"JACC Heart Fail"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2024.4470","article-title":"Interpreting population mean treatment effects in the Kansas City Cardiomyopathy Questionnaire: a patient-level meta-analysis","volume":"10","author":"Abdel Jawad M","year":"2025","unstructured":"Abdel Jawad M, Jones PG, Arnold SV, et al.. Interpreting population mean treatment effects in the Kansas City Cardiomyopathy Questionnaire: a patient-level meta-analysis. JAMA Cardiol. 2025, 10:32-40. 10.1001\/jamacardio.2024.4470","journal-title":"JAMA Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1810","article-title":"Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction","volume":"22","author":"Butler J","year":"2020","unstructured":"Butler J, Khan MS, Mori C, et al.. Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction. Eur J Heart Fail. 2020, 22:999-1005. 10.1002\/ejhf.1810","journal-title":"Eur J Heart Fail"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/496671-a-review-of-the-current-literature-regarding-sodium-glucose-cotransporter-2-inhibitors-in-heart-failure-with-preserved-ejection-fraction-and-timing-of-initiating-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T22:21:03Z","timestamp":1785709263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/496671-a-review-of-the-current-literature-regarding-sodium-glucose-cotransporter-2-inhibitors-in-heart-failure-with-preserved-ejection-fraction-and-timing-of-initiating-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,2]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.113821","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,2]]}}}